Report Detail
Global Recombinant Human Granulocyte Colony-Stimulating Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
- RnM3846363 |
- 02 July, 2024 |
- Global |
- 112 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Recombinant Human Granulocyte Colony-Stimulating market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Granulocyte-colony stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
The Global Info Research report includes an overview of the development of the Recombinant Human Granulocyte Colony-Stimulating industry chain, the market status of Chemotherapy Induced Neutropenia (Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)), Before Blood Donation (Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Recombinant Human Granulocyte Colony-Stimulating.
Regionally, the report analyzes the Recombinant Human Granulocyte Colony-Stimulating markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Recombinant Human Granulocyte Colony-Stimulating market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Recombinant Human Granulocyte Colony-Stimulating market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Recombinant Human Granulocyte Colony-Stimulating industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (KG), revenue generated, and market share of different by Type (e.g., Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Recombinant Human Granulocyte Colony-Stimulating market.
Regional Analysis: The report involves examining the Recombinant Human Granulocyte Colony-Stimulating market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Recombinant Human Granulocyte Colony-Stimulating market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Recombinant Human Granulocyte Colony-Stimulating:
Company Analysis: Report covers individual Recombinant Human Granulocyte Colony-Stimulating manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Recombinant Human Granulocyte Colony-Stimulating This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Chemotherapy Induced Neutropenia, Before Blood Donation).
Technology Analysis: Report covers specific technologies relevant to Recombinant Human Granulocyte Colony-Stimulating. It assesses the current state, advancements, and potential future developments in Recombinant Human Granulocyte Colony-Stimulating areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Recombinant Human Granulocyte Colony-Stimulating market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Recombinant Human Granulocyte Colony-Stimulating market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others
Market segment by Application
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others
Major players covered
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Human Granulocyte Colony-Stimulating product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Recombinant Human Granulocyte Colony-Stimulating, with price, sales, revenue and global market share of Recombinant Human Granulocyte Colony-Stimulating from 2019 to 2024.
Chapter 3, the Recombinant Human Granulocyte Colony-Stimulating competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Human Granulocyte Colony-Stimulating breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Recombinant Human Granulocyte Colony-Stimulating market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Human Granulocyte Colony-Stimulating.
Chapter 14 and 15, to describe Recombinant Human Granulocyte Colony-Stimulating sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope of Recombinant Human Granulocyte Colony-Stimulating
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Lenograstim (Granocyte)
- 1.3.3 Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
- 1.3.4 Others
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Chemotherapy Induced Neutropenia
- 1.4.3 Before Blood Donation
- 1.4.4 Stem Cell Transplants
- 1.4.5 Others
- 1.5 Global Recombinant Human Granulocyte Colony-Stimulating Market Size & Forecast
- 1.5.1 Global Recombinant Human Granulocyte Colony-Stimulating Consumption Value (2019 & 2023 & 2030)
- 1.5.2 Global Recombinant Human Granulocyte Colony-Stimulating Sales Quantity (2019-2030)
- 1.5.3 Global Recombinant Human Granulocyte Colony-Stimulating Average Price (2019-2030)
2 Manufacturers Profiles
- 2.1 Amgen
- 2.1.1 Amgen Details
- 2.1.2 Amgen Major Business
- 2.1.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.1.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Amgen Recent Developments/Updates
- 2.2 Qilu Pharmaceutical
- 2.2.1 Qilu Pharmaceutical Details
- 2.2.2 Qilu Pharmaceutical Major Business
- 2.2.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.2.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Qilu Pharmaceutical Recent Developments/Updates
- 2.3 Shijiazhuang Pharmaceutical
- 2.3.1 Shijiazhuang Pharmaceutical Details
- 2.3.2 Shijiazhuang Pharmaceutical Major Business
- 2.3.3 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.3.4 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 Shijiazhuang Pharmaceutical Recent Developments/Updates
- 2.4 Kyowa Hakko Kirin
- 2.4.1 Kyowa Hakko Kirin Details
- 2.4.2 Kyowa Hakko Kirin Major Business
- 2.4.3 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.4.4 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Kyowa Hakko Kirin Recent Developments/Updates
- 2.5 Gensci
- 2.5.1 Gensci Details
- 2.5.2 Gensci Major Business
- 2.5.3 Gensci Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.5.4 Gensci Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Gensci Recent Developments/Updates
- 2.6 Amoytop Biotech
- 2.6.1 Amoytop Biotech Details
- 2.6.2 Amoytop Biotech Major Business
- 2.6.3 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.6.4 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Amoytop Biotech Recent Developments/Updates
- 2.7 Hangzhou Jiuyuan
- 2.7.1 Hangzhou Jiuyuan Details
- 2.7.2 Hangzhou Jiuyuan Major Business
- 2.7.3 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.7.4 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Hangzhou Jiuyuan Recent Developments/Updates
- 2.8 Huaxin
- 2.8.1 Huaxin Details
- 2.8.2 Huaxin Major Business
- 2.8.3 Huaxin Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.8.4 Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Huaxin Recent Developments/Updates
- 2.9 Triprime
- 2.9.1 Triprime Details
- 2.9.2 Triprime Major Business
- 2.9.3 Triprime Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.9.4 Triprime Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.9.5 Triprime Recent Developments/Updates
- 2.10 Sinovac
- 2.10.1 Sinovac Details
- 2.10.2 Sinovac Major Business
- 2.10.3 Sinovac Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.10.4 Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Sinovac Recent Developments/Updates
- 2.11 Zhaoke
- 2.11.1 Zhaoke Details
- 2.11.2 Zhaoke Major Business
- 2.11.3 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.11.4 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.11.5 Zhaoke Recent Developments/Updates
- 2.12 Kawin
- 2.12.1 Kawin Details
- 2.12.2 Kawin Major Business
- 2.12.3 Kawin Recombinant Human Granulocyte Colony-Stimulating Product and Services
- 2.12.4 Kawin Recombinant Human Granulocyte Colony-Stimulating Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.12.5 Kawin Recent Developments/Updates
3 Competitive Environment: Recombinant Human Granulocyte Colony-Stimulating by Manufacturer
- 3.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Manufacturer (2019-2024)
- 3.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Manufacturer (2019-2024)
- 3.3 Global Recombinant Human Granulocyte Colony-Stimulating Average Price by Manufacturer (2019-2024)
- 3.4 Market Share Analysis (2023)
- 3.4.1 Producer Shipments of Recombinant Human Granulocyte Colony-Stimulating by Manufacturer Revenue ($MM) and Market Share (%): 2023
- 3.4.2 Top 3 Recombinant Human Granulocyte Colony-Stimulating Manufacturer Market Share in 2023
- 3.4.2 Top 6 Recombinant Human Granulocyte Colony-Stimulating Manufacturer Market Share in 2023
- 3.5 Recombinant Human Granulocyte Colony-Stimulating Market: Overall Company Footprint Analysis
- 3.5.1 Recombinant Human Granulocyte Colony-Stimulating Market: Region Footprint
- 3.5.2 Recombinant Human Granulocyte Colony-Stimulating Market: Company Product Type Footprint
- 3.5.3 Recombinant Human Granulocyte Colony-Stimulating Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Recombinant Human Granulocyte Colony-Stimulating Market Size by Region
- 4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Region (2019-2030)
- 4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Region (2019-2030)
- 4.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Average Price by Region (2019-2030)
- 4.2 North America Recombinant Human Granulocyte Colony-Stimulating Consumption Value (2019-2030)
- 4.3 Europe Recombinant Human Granulocyte Colony-Stimulating Consumption Value (2019-2030)
- 4.4 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Consumption Value (2019-2030)
- 4.5 South America Recombinant Human Granulocyte Colony-Stimulating Consumption Value (2019-2030)
- 4.6 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Consumption Value (2019-2030)
5 Market Segment by Type
- 5.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Type (2019-2030)
- 5.2 Global Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Type (2019-2030)
- 5.3 Global Recombinant Human Granulocyte Colony-Stimulating Average Price by Type (2019-2030)
6 Market Segment by Application
- 6.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Application (2019-2030)
- 6.2 Global Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Application (2019-2030)
- 6.3 Global Recombinant Human Granulocyte Colony-Stimulating Average Price by Application (2019-2030)
7 North America
- 7.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Type (2019-2030)
- 7.2 North America Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Application (2019-2030)
- 7.3 North America Recombinant Human Granulocyte Colony-Stimulating Market Size by Country
- 7.3.1 North America Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Country (2019-2030)
- 7.3.2 North America Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Country (2019-2030)
- 7.3.3 United States Market Size and Forecast (2019-2030)
- 7.3.4 Canada Market Size and Forecast (2019-2030)
- 7.3.5 Mexico Market Size and Forecast (2019-2030)
8 Europe
- 8.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Type (2019-2030)
- 8.2 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Application (2019-2030)
- 8.3 Europe Recombinant Human Granulocyte Colony-Stimulating Market Size by Country
- 8.3.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Country (2019-2030)
- 8.3.2 Europe Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Country (2019-2030)
- 8.3.3 Germany Market Size and Forecast (2019-2030)
- 8.3.4 France Market Size and Forecast (2019-2030)
- 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
- 8.3.6 Russia Market Size and Forecast (2019-2030)
- 8.3.7 Italy Market Size and Forecast (2019-2030)
9 Asia-Pacific
- 9.1 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Type (2019-2030)
- 9.2 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Application (2019-2030)
- 9.3 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Market Size by Region
- 9.3.1 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Region (2019-2030)
- 9.3.2 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Region (2019-2030)
- 9.3.3 China Market Size and Forecast (2019-2030)
- 9.3.4 Japan Market Size and Forecast (2019-2030)
- 9.3.5 Korea Market Size and Forecast (2019-2030)
- 9.3.6 India Market Size and Forecast (2019-2030)
- 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
- 9.3.8 Australia Market Size and Forecast (2019-2030)
10 South America
- 10.1 South America Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Type (2019-2030)
- 10.2 South America Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Application (2019-2030)
- 10.3 South America Recombinant Human Granulocyte Colony-Stimulating Market Size by Country
- 10.3.1 South America Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Country (2019-2030)
- 10.3.2 South America Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Country (2019-2030)
- 10.3.3 Brazil Market Size and Forecast (2019-2030)
- 10.3.4 Argentina Market Size and Forecast (2019-2030)
11 Middle East & Africa
- 11.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Type (2019-2030)
- 11.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Application (2019-2030)
- 11.3 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Market Size by Country
- 11.3.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Quantity by Country (2019-2030)
- 11.3.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Consumption Value by Country (2019-2030)
- 11.3.3 Turkey Market Size and Forecast (2019-2030)
- 11.3.4 Egypt Market Size and Forecast (2019-2030)
- 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
- 11.3.6 South Africa Market Size and Forecast (2019-2030)
12 Market Dynamics
- 12.1 Recombinant Human Granulocyte Colony-Stimulating Market Drivers
- 12.2 Recombinant Human Granulocyte Colony-Stimulating Market Restraints
- 12.3 Recombinant Human Granulocyte Colony-Stimulating Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Recombinant Human Granulocyte Colony-Stimulating and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Recombinant Human Granulocyte Colony-Stimulating
- 13.3 Recombinant Human Granulocyte Colony-Stimulating Production Process
- 13.4 Recombinant Human Granulocyte Colony-Stimulating Industrial Chain
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Recombinant Human Granulocyte Colony-Stimulating Typical Distributors
- 14.3 Recombinant Human Granulocyte Colony-Stimulating Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Recombinant Human Granulocyte Colony-Stimulating. Industry analysis & Market Report on Recombinant Human Granulocyte Colony-Stimulating is a syndicated market report, published as Global Recombinant Human Granulocyte Colony-Stimulating Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Recombinant Human Granulocyte Colony-Stimulating market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
